Evidence map›Paper›PMID 42737515›Full record

ReviewInternational journal of molecular sciences2026

Overcoming the Limitations of Protein A: Evolution of Bacterial Protein-Based and Synthetic Affinity Ligands for High-Performance IgG Purification.

Larisa N Ikryannikova, Mikhail N Tereshin, Milena V Baskova, Kristina P Telepenina, Neonila V Gorokhovets, Daniel R Bayzigitov, Eugenia A Gurylina, Vasiliy N Stepanenko, Tatiana D Melikhova

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Larisa N IkryannikovaI.M. Sechenov First Moscow State Medical University, Institute of Translational Medicine and Biotechnology, 8/2 Trubetskaya Str., 119991 Moscow, Russia.
Mikhail N TereshinI.M. Sechenov First Moscow State Medical University, Institute of Translational Medicine and Biotechnology, 8/2 Trubetskaya Str., 119991 Moscow, Russia.
Milena V BaskovaI.M. Sechenov First Moscow State Medical University, Institute of Translational Medicine and Biotechnology, 8/2 Trubetskaya Str., 119991 Moscow, Russia.
Kristina P TelepeninaI.M. Sechenov First Moscow State Medical University, Institute of Translational Medicine and Biotechnology, 8/2 Trubetskaya Str., 119991 Moscow, Russia.
Neonila V GorokhovetsI.M. Sechenov First Moscow State Medical University, Institute of Translational Medicine and Biotechnology, 8/2 Trubetskaya Str., 119991 Moscow, Russia.
Daniel R BayzigitovR-Pharm Group Pharmaceutical Company, 119421 Moscow, Russia.
Eugenia A GurylinaR-Pharm Group Pharmaceutical Company, 119421 Moscow, Russia.
Vasiliy N StepanenkoI.M. Sechenov First Moscow State Medical University, Institute of Translational Medicine and Biotechnology, 8/2 Trubetskaya Str., 119991 Moscow, Russia.
Tatiana D MelikhovaI.M. Sechenov First Moscow State Medical University, Institute of Translational Medicine and Biotechnology, 8/2 Trubetskaya Str., 119991 Moscow, Russia.ORCID 0009-0008-7203-3449

Funding

GREENVAN, LLC
6 · The paper itself

Abstract

Monoclonal antibodies (mAbs) are widely used as therapeutic molecules for the treatment of serious diseases, primarily cancer. The market for mAbs is one of the fastest-growing segments of the biopharmaceuticals industry. Purification is a crucial stage in the production of mAbs. While staphylococcal protein A (SpA) affinity chromatography remains the gold standard in industrial mAb purification, its limitations-low alkaline stability and insufficient binding capacity of SpA, as well as the need for harsh acidic elution conditions-have driven extensive efforts for novel progressive affinity ligands. This review focuses on the development and performance of bacterial protein-based affinity resins for the purification of class G immunoglobulins (IgGs), including conventional proteins A and G, the promising protein L, and the more recently discovered protein M (from

Indexed as

Bacterial ProteinsChromatography, AffinityImmunoglobulin GStaphylococcal Protein AAnimalsAntibodies, MonoclonalHumansLigandsAntibodies, MonoclonalBacterial ProteinsImmunoglobulin GLigandsStaphylococcal Protein Aaffinity chromatographyhybrid proteinsIgGsimmunoglobulin-binding proteins (IBPs)mAbs purificationprotein A

Identifiers

PMID42737515
PMCPMC13565897

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.